Quent Capital’s Ocular Therapeutix OCUL Stock Holding History

Quent Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.03K	Sell	410 -244	-37%	-$2.21K	﹤0.01%	1388
2026 Q1	$5.54K	Hold	654	–	–	﹤0.01%	1258
2025 Q4	$7.94K	Sell	654 -96	-13%	-$1.17K	﹤0.01%	1198
2025 Q3	$8.77K	Buy	+750	New	+$8.97K	﹤0.01%	1039
2025 Q2	–	Sell	-750	Closed	-$5.5K	–	944
2025 Q1	$5.5K	Hold	750	–	–	﹤0.01%	1001
2024 Q4	$6.41K	Hold	750	–	–	﹤0.01%	995
2024 Q3	$6.53K	Hold	750	–	–	﹤0.01%	1055
2024 Q2	$5.13K	Hold	750	–	–	﹤0.01%	1083
2024 Q1	$6.83K	Sell	750 -3	-0.4%	-$21	﹤0.01%	1071
2023 Q4	$3.36K	Buy	753 +108	+17%	+$319	﹤0.01%	1138
2023 Q3	$2.02K	Buy	645 +244	+61%	+$998	﹤0.01%	1175
2023 Q2	$2.07K	Buy	+401	New	+$2.38K	﹤0.01%	1182
2023 Q1	–	Sell	-490	Closed	-$1.38K	–	1338
2022 Q4	$1.38K	Buy	+490	New	+$1.62K	﹤0.01%	1190

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Quent Capital's OCUL Position: Q2 2026 in Review

Quent Capital reduced its Ocular Therapeutix (OCUL) stake by 37% in Q2 2026, selling an estimated $2.21K and leaving 410 shares worth $4.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Quent Capital first reported a position in OCUL in Q4 2022 and has held it in 13 quarters since. The position peaked at $8.77K in Q3 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Quent Capital held 410 shares of Ocular Therapeutix worth $4.03K as of Q2 2026.
Quent Capital sold 244 Ocular Therapeutix shares in Q2 2026, an estimated $2.21K.
Ocular Therapeutix made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1388 holding.
Quent Capital first reported a position in Ocular Therapeutix in Q4 2022 and has held it in 13 quarters since.
Quent Capital's Ocular Therapeutix position peaked at $8.77K in Q3 2025.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.